Underlying and Urgent

Data from the Journal of the American Medical Association reveals the devastating impact of underlying health conditions on patients with COVID-19 (see figure below). Those with hypertension, obesity, and diabetes, among others, face a significantly higher risk of hospitalization and death. 

Effective treatment for these diseases has never been more relevant and urgent.

The top three - hypertension, diabetes, and obesity - are highly prevalent in the US population. Yet, they present different challenges.

Hypertension affects 108 million people (approx. 45% of US adults) of which 81% (87 million) have been prescribed medication (2016 CDC and CHS data). 

Similarly, diabetes affects 30 million people (approximately 12% of US adults) of which 73% (22 million) are diagnosed and treated (2015 CDC data).

In contrast, according to the CDC, there are 95 million people with obesity (approximately 39% of US adults), of which only 20% (19 million) have been prescribed anti-obesity medication (Obesity Society data).

As patients and physicians absorb these realities, how will treatment mindsets and behaviors change to address acute, underlying risks? What can pharmaceutical companies do to advance outcomes, optimize treatment, provide patient access, and support adherence?

To help address these underlying health risks, pharmaceutical companies need to think more like healthcare providers. 

By putting the Spotlight on patients, Luminous can work with you to re-envision the patient journey, identify treatment drivers, and activate payers and healthcare providers.